Cited by 770Immune cells in cancerCancer Immunotherapy and BiomarkersChemokine receptors and signaling

The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.

Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy

Open access

Highfill, Steven L., Cui, Yongzhi, Giles, Amber J., Smith, Jillian P., Zhang, Hua, Morse, Elizabeth, Kaplan, Rosandra N., Mackall, Crystal L.·2014·Science Translational Medicine

DOI 10.1126/scitranslmed.3007974PMC PMC6980372

Open this paper in CoChat — free account

Abstract

Preventing trafficking of myeloid-derived suppressor cells to the tumor site enhances the efficiency of checkpoint blockade.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.3007974

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · cited 1×
“Signaling of PD1 on T cells via PD-L1 (B7-H1) or PD-L2 (B7-DC) inhibits T cell receptor–mediated activation by recruitment of the SHP2 phosphatase (2).”
Background
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 1×
“Combination regimens appear to be even more potent with response rates of 53% in metastatic melanoma (22).”
Background
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 2×
“These results are consistent with previous reports demonstrating that GrMDSCs at the tumor site are highly dependent on migration from the BM or spleen and undergo minimal proliferation within the tumor bed (13).”
BackgroundResult
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,261

Show all 50 references

Sorted by citations

Items 401–500 of 770

Metabolic Factors Affecting Tumor Immunogenicity: What Is Happening at the Cellular Level?
Sayed, R. E., Haibe, Y., Amhaz, G., Bouferraa, Y., & Shamseddine, A. I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042142 · Cited by 27
Combined Effects of Myeloid Cells in the Neuroblastoma Tumor Microenvironment
Frosch, J., Leontari, I., & Anderson, J. (2021) · Cancers · doi:10.3390/cancers13071743 · Cited by 28
“Furthermore, studies on rhabdomyosarcoma in mice have shown that disruption of CXCR2-dependent MDSC trafficking to the tumor resulted in significantly increased antitumor effects [79].”
Background
Myeloid cells in COVID-19 microenvironment
Qin, G., Liu, S., Li, Y., Yu, W., & Zhang, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00792-0 · Cited by 27
miR-150-5p-Containing Extracellular Vesicles Are a New Immunoregulator That Favor the Progression of Lung Cancer in Hypoxic Microenvironments by Altering the Phenotype of NK Cells
Chang, W., Tsai, M., Hung, J., Wu, K., Tsai, Y., Huang, Y., Chang, C., Tsai, P.-H., & Hsu, Y. (2021) · Cancers · doi:10.3390/cancers13246252 · Cited by 27
“This results in the recruitment of various immune populations, including tumor-associated macrophages, neutrophils, mast cells, and myeloidderived suppressor cells (MDSCs), which interact with cancer cells and eventually shape an immunosuppressive environment, with diminished anti-cancer abilities and enhanced tumor-p…”
Background
Nanotechnology Applications in Breast Cancer Immunotherapy
Wang, R., Kumar, P., Reda, M. M., Wallstrum, A., Crumrine, N. A., Ngamcherdtrakul, W., & Yantasee, W. (2023) · Small · doi:10.1002/smll.202308639 · Cited by 30
Altered activation state of circulating neutrophils in patients with neovascular age-related macular degeneration
Nielsen, M. K., Hector, S. M., Allen, K., Subhi, Y., & Sørensen, T. L. (2017) · Immunity & Ageing · doi:10.1186/s12979-017-0100-9 · Cited by 28
Targeting tumor microenvironment for non-small cell lung cancer immunotherapy
Wang, L., Jia, Q., Chu, Q., & Zhu, B. (2023) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2022.11.001 · Cited by 30
Unlocking antitumor immunity with adenosine receptor blockers
Remley, V. A., Linden, J. M., Bauer, T. W., & Dimastromatteo, J. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2023.63 · Cited by 27
Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment
Deng, J., Thennavan, A., Shah, S. M., Bagdatlioglu, E., Klar, N. J., Heguy, A., Marier, C., Meyn, P., Zhang, Y., Labbe, K. E., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05936-4 · Cited by 26
Addressing Resistance to Immune Checkpoint Inhibitor Therapy: An Urgent Unmet Need
Hu‐Lieskovan, S., Malouf, G. G., Jacobs, I. A., Chou, J., Liu, L., & Johnson, M. L. (2021) · Future Oncology · doi:10.2217/fon-2020-0967 · Cited by 26
H. pylori infection induces CXCL8 expression and promotes gastric cancer progress through downregulating KLF4
Liu, Z., Wu, X. Q., Tian, Y., Zhang, W., qiao, S., Xu, W., Liu, Y., & Wang, S. (2021) · Molecular Carcinogenesis · doi:10.1002/mc.23309 · Cited by 26
“reported that CXCR2 is required for the trafficking of MDSCs to the tumour bed and that inhibiting MDSC trafficking to the tumour enhanced the potency of PD1 checkpoint blockade.(48)”
Background
Tumor and Peripheral Immune Status in Soft Tissue Sarcoma: Implications for Immunotherapy
Sousa, L. M., Almeida, J. S., Fortes-Andrade, T., Santos-Rosa, M., Freitas-Tavares, P., Casanova, J., & Rodrigues‐Santos, P. (2021) · Cancers · doi:10.3390/cancers13153885 · Cited by 27
“These immature myeloid cells can be phenotypically divided into early-MDSCs (e-MDSCs), monocytic MDSCs (M-MDSCs), and polymorphonuclear MDSCs (PMN-MDSCs) [60,61].”
Background
Subpopulations of M-MDSCs from mice infected by an immunodeficiency-causing retrovirus and their differential suppression of T- vs B-cell responses
O’Connor, M. A., Fu, W. W., Green, K. A., & Green, W. R. (2015) · Virology · doi:10.1016/j.virol.2015.07.020 · Cited by 26
Checkpoint inhibitors and acute myelogenous leukemia: promises and challenges
Alfayez, M., & Borthakur, G. M. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1459184 · Cited by 26
“MDSCs express high levels of C–C chemokine receptor 1 (CCR1) or CXC chemokine receptor 2 (CXCR2) and combination of a CCR1 antagonist with CPI might have a future value in optimizing immune response [122,123].”
Background
Inflammation and Cancer
Kumar, S., Chan, C. J., & Coussens, L. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-374279-7.17002-x · Cited by 28
Targeting myeloid-derived suppressor cells promotes antiparasitic T-cell immunity and enhances the efficacy of PD-1 blockade
Zhang, C., Wang, H., Aji, T., Li, L., Li, Y., Ainiwaer, A., Rousu, Z., Li, J., Wang, M., Deng, B., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50754-7 · Cited by 25
STX2 promotes colorectal cancer metastasis through a positive feedback loop that activates the NF-κB pathway
Wang, Y., Xu, H., Jiao, H., Wang, S., Xiao, Z., Zhao, Y., Bi, J., Wei, W., Liu, S., Qiu, J., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0675-x · Cited by 25
STAT3 Silencing and TLR7/8 Pathway Activation Repolarize and Suppress Myeloid-Derived Suppressor Cells From Breast Cancer Patients
Safarzadeh, E., Mohammadi, A., Mansoori, B., Duijf, P. H. G., Hashemzadeh, S., Khaze, V., Kazemi, T., Derakhshani, A., Silvestris, N., & Baradaran, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.613215 · Cited by 25
“showed that the suppression of the antitumor immune response by MDSCs could be significantly inhibited by controlling the CXCR2 factor, which is involved in the migration of MDSCs to the tumor tissue (20).”
Background
Impact of cancer cell-intrinsic features on neutrophil behavior
Duits, D. E. M., & de Visser, K. E. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101546 · Cited by 27
Chemokines as Regulators of Neutrophils: Focus on Tumors, Therapeutic Targeting, and Immunotherapy
Bonecchi, R., Mantovani, A., & Jaillon, S. (2022) · Cancers · doi:10.3390/cancers14030680 · Cited by 27
“The efficacy of anti-PD-1 treatment was improved by genetic deficiency or inhibition of CXCR1/2 in murine models of oral and lung carcinomas, rhabdomyosarcomas [136], pancreatic adenocarcinoma [147], and prostate cancer [155].”
Background
CCL2-mediated monocytes regulate immune checkpoint blockade resistance in pancreatic cancer
Li, X., He, G., Liu, J., Yan, M., Shen, M., Xu, L., An, M. J., Huang, J., & Gao, Z. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108598 · Cited by 25
Current Landscape of Immunotherapy for Advanced Sarcoma
Albarrán, V., Villamayor, M. L., Pozas, J., Chamorro, J., Rosero, D. I., Román, M. S., Guerrero, P., de Aguado, P. P., Calvo, J. C., de Quevedo, C. G., et al. (2023) · Cancers · doi:10.3390/cancers15082287 · Cited by 25
“[65] showed that pediatric patients with advanced sarcoma display elevated serum levels of CXCL8, which are associated with poor survival rates.”
Background
The double‐edged role of neutrophil heterogeneity in inflammatory diseases and cancers
Zhou, W., Cao, X., Xu, Q., Qu, J., & Sun, Y. (2023) · MedComm · doi:10.1002/mco2.325 · Cited by 25
Arginine auxotrophic gene signature in paediatric sarcomas and brain tumours provides a viable target for arginine depletion therapies
Vardon, A., Dandapani, M., Cheng, D., Cheng, P., Santo, C. D., & Mussai, F. (2017) · Oncotarget · doi:10.18632/oncotarget.18843 · Cited by 26
Improved Cancer Immunochemotherapy via Optimal Co-delivery of Chemotherapeutic and Immunomodulatory Agents
Chen, Y., Sun, J., Huang, Y., Lu, B., & Li, S. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00717 · Cited by 26
Regression and Eradication of Triple-Negative Breast Carcinoma in 4T1 Mouse Model by Combination Immunotherapies
Nahar, S., Huang, Y., Nagy, B. A., Zebala, J. A., Maeda, D. Y., Rudloff, U., Oppenheim, J. J., & Yang, D. (2023) · Cancers · doi:10.3390/cancers15082366 · Cited by 24
“Prior studies showed that monotherapy with CXCR1/2 inhibitor SX682 or with anti-PD1 ICB alone had no significant effect on tumor growth or on the survival rate, but combination treatment reduced tumor growth and improved survival [39,40].”
Background
GLP1 alleviates oleic acid-propelled lipocalin-2 generation by tumor-infiltrating CD8+ T cells to reduce polymorphonuclear MDSC recruitment and enhances viral immunotherapy in pancreatic cancer
Wu, J., Qian, P., Han, Y., Xu, C., Mao, X., Zhan, P., Wei, J., & Dong, J. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01260-3 · Cited by 24
“MDSCs can induce T-cell apoptosis and inhibit the proliferation and expansion of CD8 + T cells through various mechanisms, thus playing crucial roles in tumor immune escape and therapeutic resistance [5 – 7].”
MNDA promotes immunosuppression in microsatellite instability-high colorectal cancer by facilitating PMN-MDSC infiltration via H3K18 lactylation
Zhang, X., Wang, W., Cai, X., Chen, X.-Q., Feng, Q., Yang, Q., Li, J.-B., Xiong, W., & Wu, T. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07097-8 · Cited by 25
“Increased CXCR2 expression is associated with increased MDSC infiltration, angiogenesis, and therapeutic resistance in multiple cancers, including lung and pancreatic cancers [46].”
Autologous cytokine‐induced killer ( CIK ) cells enhance the clinical response to PD‐1 blocking antibodies in patients with advanced non‐small cell lung cancer: A preliminary study
Han, Y., Mu, D., Liu, T., Zhang, H., Zhang, J., Li, S., Wang, R., Du, W., Hui, Z., Zhang, X., et al. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13731 · Cited by 24
Self-citation
Class I histone deacetylase inhibition promotes CD8 T cell activation in ovarian cancer
McCaw, T. R., Goel, N., Brooke, D. J., Katre, A. A., Londoño, A. I., Smith, H. J., Randall, T. D., & Arend, R. C. (2020) · Cancer Medicine · doi:10.1002/cam4.3337 · Cited by 24
Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy
Liu, J., Tao, H., Yuan, T., Li, J., Li, J., Liang, H., Huang, Z., & Zhang, E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.992611 · Cited by 27
“The massive accumulation of MDSCs in tumor tissues will limit the inhibitory effect of ICIs on tumors (38).”
Background
Drug Resistance in Cancers: A Free Pass for Bullying
Li, J., Li, X., & Guo, Q. (2022) · Cells · doi:10.3390/cells11213383 · Cited by 24
“The level of MDSCs is also related to patient responses to CTLA-4/ipilimumab [55,56] and PD-1 inhibition [57,58].”
Background
Invasion and metastasis—recent advances and future challenges
Chambers, A. F., & Werb, Z. (2015) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1269-z · Cited by 23
Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002
Ring, E. K., Li, R., Moore, B. P., Nan, L., Kelly, V. M., Han, X., Beierle, E. A., Markert, J. M., Leavenworth, J. W., Gillespie, G. Y., et al. (2017) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2017.09.003 · Cited by 24
Chemokine signaling axis between endothelial and myeloid cells regulates development of pulmonary hypertension associated with pulmonary fibrosis and hypoxia
Oliveira, A. C. D. S., Fu, C., Lu, Y., Williams, M. A., Pi, L., Brantly, M., Ventetuolo, C. E., Raizada, M. K., Mehrad, B., Scott, E. W., et al. (2019) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00156.2019 · Cited by 23
Tofacitinib enhances delivery of antibody-based therapeutics to tumor cells through modulation of inflammatory cells
Simon, N. C., Antignani, A., Hewitt, S. M., Gadina, M., Alewine, C., & FitzGerald, D. J. (2019) · JCI Insight · doi:10.1172/jci.insight.123281 · Cited by 23
“Various cell types within 32 the tumor microenvironment (TME) have been posited as barriers to effective treatment including 33 macrophages(1, 2), monocytes(3), fibroblasts(4), neutrophils(5), regulatory T-cells(6), and endothelial 34 cells(7).”
Background
Myeloid-derived suppressor cells in gastrointestinal cancers: A systemic review
Farshidpour, M., Ahmed∥, M., Junna, S., & Merchant, J. L. (2021) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v13.i1.1 · Cited by 24
Changes in the tumor microenvironment and outcome for TME-targeting therapy in glioblastoma: A pilot study
Ali, S., Borin, T. F., Piranlioglu, R., Ara, R., Lebedyeva, I., Angara, K., Achyut, B. R., Arbab, A. S., & Rashid, M. H. (2021) · PLoS ONE · doi:10.1371/journal.pone.0246646 · Cited by 25
Multifunctional Immunoliposomes Enhance the Immunotherapeutic Effects of PD‐L1 Antibodies against Melanoma by Reprogramming Immunosuppressive Tumor Microenvironment
Hei, Y., Yang, C., Li, Q., Mei, Z., Pan, J., Zhang, S., Xiong, C., Su, X., & Wei, S. (2021) · Small · doi:10.1002/smll.202105118 · Cited by 23
Pharmacological modulation of myeloid-derived suppressor cells to dampen inflammation
van Geffen, C., Heiss, C., Deißler, A., & Kolahian, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.933847 · Cited by 23
Myeloid checkpoints for cancer immunotherapy
Qian, Y., Yang, T., Liang, H., & Deng, M. (2022) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2022.05.07 · Cited by 24
Avoiding phagocytosis-related artifact in myeloid derived suppressor cell T-lymphocyte suppression assays
Davis, R. J., Silvin, C. J., & Allen, C. T. (2016) · Journal of Immunological Methods · doi:10.1016/j.jim.2016.11.006 · Cited by 23
The role of CCR5 in directing the mobilization and biological function of CD11b+Gr1+Ly6Clow polymorphonuclear myeloid cells in cancer
Karin, N., & Razon, H. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2245-6 · Cited by 22
Myeloid-derived suppressor cells: Cancer, autoimmune diseases, and more
Shibata, M., Nanno, K., Yoshimori, D., Nakajima, T., Takada, M., Yazawa, T., Mimura, K., Inoue, N., Watanabe, T., Tachibana, K., et al. (2022) · Oncotarget · doi:10.18632/oncotarget.28303 · Cited by 23
Driver Mutations Dictate the Immunologic Landscape and Response to Checkpoint Immunotherapy of Glioblastoma
Yeo, A. T., Shah, R., Aliazis, K., Pal, R., Xu, T., Zhang, P., Rawal, S., Rose, C. M., Varn, F. S., Appleman, V. A., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0655 · Cited by 22
“These data are consistent with prior reports that inhibition of CXCR2 reduces tumor MDSC infiltration and tumor growth in cancer models (64–67) and improved the efficacy of PD-1 immune checkpoint blockade (68, 69).”
The Clinical Significance and Involvement in Molecular Cancer Processes of Chemokine CXCL1 in Selected Tumors
Korbecki, J., Bosiacki, M., Szatkowska, I., Kupnicka, P., Chlubek, D., & Baranowska‐Bosiacka, I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084365 · Cited by 22
“Children with sarcomas have increased blood CXCL1 levels compared to healthy individuals, although a much greater increase occurs in CXCL8/IL-8 [172], whose high blood levels are associated with a poorer prognosis for patients with sarcomas.”
Background
Physiological, Tumor, and Metastatic Niches: Opportunities and Challenges for Targeting the Tumor Microenvironment
Murgai, M., Giles, A. J., & Kaplan, R. N. (2015) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2015013668 · Cited by 23
Self-citation
CXCR1/2 antagonism inhibits neutrophil function and not recruitment in cancer
Kwak, J., Nguyen, H. Q., Camai, A., Huffman, G. M., Mekvanich, S., Kenney, N. N., Zhu, X., Randolph, T. W., & Houghton, A. M. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2384674 · Cited by 23
Tumor immune microenvironment in cancer patients with leukocytosis
Kim, K. H., Sim, N. S., Chang, J. S., & Kim, Y. B. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02545-4 · Cited by 21
Pharmacological combination of nivolumab with dendritic cell vaccines in cancer immunotherapy: An overview
Calmeiro, J., Carrascal, M. A., Tavares, A. R., Ferreira, D. A., Gomes, C. M. F., Cruz, M. T., Falcão, A. C., & Neves, B. M. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105309 · Cited by 22
Combination treatment with immunogenic and anti-PD-L1 polymer-drug conjugates of advanced tumors in a transgenic MMTV-PyMT mouse model of breast cancer
Li, L., Wang, J., Radford, D. C., Kopec̆ek, J., & Yang, J. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.02.011 · Cited by 21
New developments in the mechanism and application of immune checkpoint inhibitors in cancer therapy (Review)
Wang, Y., Yang, S., Wan, L., Ling, W., Chen, H. H., & Wang, J. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5534 · Cited by 22
The G protein coupled receptor CCR5 in cancer
Upadhyaya, C., Jiao, X., Ashton, A. W., Patel, K., Kossenkov, A. V., & Pestell, R. G. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2019.11.001 · Cited by 21
“, 2012), and when disrupted, MDSC trafficking enhances anti-PD1 therapy (Highfill et al., 2014).”
Background
S100A10 promotes cancer metastasis via recruitment of MDSCs within the lungs
Li, J., Zhou, C., Gao, X., Tan, T., Zhang, M., Li, Y., Chen, H., Wang, R. L., Wang, B., Liu, J., et al. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2381803 · Cited by 20
“38,39 The function of the CXCL1 and CXCL8 is chemotactic for MDSCs, neutrophils, and monocytes and remodels the immune micro-environment of the tumor.”
Background
Cancer-specific innate and adaptive immune rewiring drives resistance to PD-1 blockade in classic Hodgkin lymphoma
Paczkowska, J., Tang, M., Wright, K., Song, L., Luu, K., Shanmugam, V., Welsh, E. L., Weirather, J. L., Besson, N. R., Olszewski, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54512-7 · Cited by 21
“…antibodies and CXCR2 antagonists, which block multiple cytokines/chemokines including IL-8, CXCL1, CXCL2 and CXCL3, suppress in ﬂ ammasome activation, myeloid cell recruitment, tumor growth and angiogenesis, and enhance the ef ﬁ cacy of PD-1 blockade in certain solid tumors 87,100 – 102,107 ,108 .”
Improving surgical treatments for hepatocellular carcinoma
Malik, A. K., Geh, D., Evans, T. R. J., Chow, P. K. H., Mann, D. A., & White, S. A. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01143-y · Cited by 24
“In parallel, strategies targeting myeloid suppressor cells 216 , TGFβ 217 or SASP 218 aim to recondition the hepatic immune microenvironment.”
Tackling Immune Targets for Breast Cancer: Beyond PD-1/PD-L1 Axis
Tabana, Y., Okoye, I., Siraki, A. G., Elahi, S., & Barakat, K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.628138 · Cited by 20
“CXCR2 also induces the migration of MDSCs, thus, promoting local immunosuppression (107).”
Background
Sustained Drug Release From Liposomes for the Remodeling of Systemic Immune Homeostasis and the Tumor Microenvironment
Zheng, A., Xie, F. X., Shi, S., Liu, S., Long, J., & Xu, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.829391 · Cited by 21
The immunoregulation effect of tumor microenvironment in pancreatic ductal adenocarcinoma
Zhang, J., Li, R., & Huang, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.951019 · Cited by 19
“CXCR2 is involved in the formation of premetastatic niche in the liver of PDAC through G-proteincoupled receptors that control neutrophil and MDSCs migration (110).”
Background
The role of spleen volume change in predicting immunotherapy response in metastatic renal cell carcinoma
Aslan, V., Kılıç, A. C. K., Özet, A., Üner, A., Günel, N., Yazıcı, O., Savaş, G., Bayrak, A., Eraslan, E., Öksüzoğlu, B. Ç., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11558-y · Cited by 23
Unfolding innate mechanisms in the cancer microenvironment: The emerging role of the mesenchyme
Koliaraki, V., Henriques, A. R., Prados, A., & Kollias, G. A. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20190457 · Cited by 20
Melanoma immunotherapy: strategies to overcome pharmacological resistance
Trojaniello, C., Vitale, M. G., Scarpato, L., Esposito, A., & Ascierto, P. A. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1745634 · Cited by 22
“Meyer et al suggested that frequency of MDSCs may be a predictive marker of response, as low frequencies identify patients more likely to benefit from ipilimumab.”
BackgroundInfluential
Good cops turn bad: The contribution of neutrophils to immune-checkpoint inhibitor treatment failures in cancer
Zhang, H., & Houghton, A. M. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107662 · Cited by 20
Self-citation
Genetically engineered exosomes for targetedly preventing premetastatic niche formation and suppressing postoperative melanoma lung metastasis
Han, X., Bi, L., Wu, Y., Yan, J., Wu, X., Zheng, R., Sun, Y., Zhang, H., Wang, Z., Wang, Y., et al. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101597 · Cited by 19
Self-citation
Genomic landscape of the immunogenicity regulation in skin melanomas with diverse tumor mutation burden
Georgoulias, G., & Zaravinos, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1006665 · Cited by 21
“Frontiers in Immunology 17 cell types, on their own and cooperatively, induce an immunesuppressive TME that prevents anti-tumor cytotoxic and Th1directed T-cell activities, mainly through the release of cytokines, chemokines, and other soluble mediators (113).”
Background
Analysis of Immune Resistance Mechanisms in TNBC: Dual Effects Inside and Outside the Tumor
Xu, J., Chen, G., Yu, S., Yao, S., Li, W., & Cheng, H. (2023) · Clinical Breast Cancer · doi:10.1016/j.clbc.2023.10.011 · Cited by 20
Myeloid derived suppressor cells in cancer, premalignancy and inflammation: A roadmap to cancer immunoprevention
Sivagnanalingam, U., Beatty, P. L., & Finn, O. J. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23206 · Cited by 19
“impacted by MDSC and patient responses are associated with the levels of circulating MDSC in the tumor microenvironment.(23,70,71)”
Background
(−)-4-O-(4-O-β-D-glucopyranosylcaffeoyl) Quinic Acid Inhibits the Function of Myeloid-Derived Suppressor Cells to Enhance the Efficacy of Anti-PD1 against Colon Cancer
Lin, H., Wu, Y.-Z., Chen, J.-P., Huang, S.-R., & Wang, Y. (2018) · Pharmaceutical Research · doi:10.1007/s11095-018-2459-5 · Cited by 18
Mechanisms of myeloid-derived suppressor cell-mediated immunosuppression in colorectal cancer and related therapies
Nie, S.-C., Jing, Y., Lu, L., Ren, S.-S., Ji, G., & Xu, H.-C. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v16.i5.1690 · Cited by 22
“…lung cancer Koinis et al [91] IL-17 Breast cancer Ma et al [98] flubendazole STAT3 Melanoma Li et al [96] CXCR2 Rhabdomyosarcoma Highfill et al [99] IL-6 STAT3-DNMT Colorectal cancer Smith et al [97] G-CSF Colorectal cancer Li et al [107] Carnosic acid Cisplatin Lung cancer Liu et al [101]…”
Dual Oxygen‐Supply Immunosuppression‐Inhibiting Nanomedicine to Avoid the Intratumoral Recruitment of Myeloid‐Derived Suppressor Cells
Yang, Z., Zuo, H., Hou, Y., Zhou, S., Zhang, Y., Yang, W., He, J., Shen, X., & Peng, Q. (2024) · Small · doi:10.1002/smll.202406860 · Cited by 19
Precision cytokine modulation to overcome tumor microenvironment-driven resistance to immune checkpoint blockade
Wang, X., Wang, J., Wang, Q., Ding, G., Huang, Y., & Feng, Y. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189536 · Cited by 19
Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma
Kimbara, S., & Kondo, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i33.7440 · Cited by 18
The chemokine receptor CXCR2 contributes to murine adipocyte development
Dyer, D. P., Nebot, J. B., Kelly, C. J., Medina‐Ruiz, L., Schuette, F., & Graham, G. J. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.1a0618-216rr · Cited by 18
Value of CXCL8–CXCR1/2 axis in neoadjuvant chemotherapy for triple-negative breast cancer patients: a retrospective pilot study
Wang, R., Ji, P., Gong, Y., Shao, Z., & Chen, S. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05660-z · Cited by 18
Reprogramming the neuroblastoma tumor immune microenvironment to enhance GPC2 CAR T cells
Giudice, A. M., Roth, S. L., Matlaga, S., Cresswell-Clay, E., Mishra, P., Schürch, P. M., Boateng-Antwi, K. A. M., Samanta, M., Pascual‐Pasto, G., Zecchino, V. P., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.05.025 · Cited by 19
Addressing clinical needs in NSCLC immunotherapy: Mechanisms of resistance and promising combination strategies
Kang, K., Liu, S., Yao, Z., Xue, J., & Lu, Y. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102315 · Cited by 17
Cancer Immunotherapy in Combination with Radiotherapy and/or Chemotherapy: Mechanisms and Clinical Therapy
Wang, X., & Jing, J. (2025) · MedComm · doi:10.1002/mco2.70346 · Cited by 21
Surface TREM2 on circulating M-MDSCs as a novel prognostic factor for adults with treatment-naïve diffuse large B-cell lymphoma
Wang, H., Yang, F.-C., Yang, C., Liu, Y., Ko, P., Li, C.-J., Tsai, C., Chung, Y., & Chen, N. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00399-x · Cited by 18
“Recent studies have spotlighted myeloid-derived suppressive cells (MDSCs) as one of the culprits in impairing the function of CTLs and attenuating the effectiveness of immunotherapies [7–11]; inhibition of trafficking MDSCs into tumor sites could enhance the efficacy of immunotherapies [12].”
Background
Association between Fluoxetine Use and Overall Survival among Patients with Cancer Treated with PD-1/L1 Immunotherapy
Magagnoli, J., Narendran, S., Pereira, F., Cummings, T. H., Hardin, J. W., Sutton, S. S., & Ambati, J. (2023) · Pharmaceuticals · doi:10.3390/ph16050640 · Cited by 16
Plac1 Is a Key Regulator of the Inflammatory Response and Immune Tolerance In Mammary Tumorigenesis
Yuan, H., Wang, X., Shi, C., Jin, L., Hu, J., Zhang, A., Li, J., Vijayendra, N., Doodala, V., Weiss, S., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-24022-w · Cited by 17
PD-1/PD-L1 blockade in paediatric cancers: What does the future hold?
Moreno-Vicente, J., Beers, S. A., & Gray, J. C. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.04.025 · Cited by 16
Emergency myelopoiesis contributes to immune cell exhaustion and pulmonary vascular remodelling
Fu, C., Lu, Y., Williams, M. A., Brantly, M., Ventetuolo, C. E., Morel, L. M., Mehrad, B., Scott, E. W., & Bryant, A. J. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14945 · Cited by 17
Explicating the Pivotal Pathogenic, Diagnostic, and Therapeutic Biomarker Potentials of Myeloid-Derived Suppressor Cells in Glioblastoma
Richard, S. A. (2020) · Disease Markers · doi:10.1155/2020/8844313 · Cited by 17
“Also, studies have demonstrated that GBM was capable of secreting IL-8 which in turn triggered the trafficking of MDSCs into the tumor environment via the CXCR2 receptor which functions as MIF receptors [36, 38].”
Background
The Role of Myeloid-Derived Suppressor Cells in Tumor Growth and Metastasis
Bayık, D., Lee, J., & Lathia, J. D. (2022) · Experientia supplementum · doi:10.1007/978-3-030-91311-3_7 · Cited by 17
The promise of targeting heme and mitochondrial respiration in normalizing tumor microenvironment and potentiating immunotherapy
Akter, Z., Salamat, N., Ali, M. Y., & Li, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1072739 · Cited by 17
BTK inhibition potentiates anti-PD-L1 treatment in murine melanoma: potential role for MDSC modulation in immunotherapy
Sun, S. H., Angell, C. D., Savardekar, H., Sundi, D., Abood, D., Benner, B. N., DiVincenzo, M. J., Duggan, M. C., Choueiry, F., Mace, T. A., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03497-1 · Cited by 16
“Other strategies to enhance the therapeutic efficacy of immune checkpoint blockade via inhibition of MDSC have been studied, including histamine administration to suppress MDSC-generated ROS [49], blockade of the CXCR2 chemokine receptor [50], and inhibition of CCRK (a cyclin-dependent kinase that promotes secretion o…”
Coactivation of innate immune suppressive cells induces acquired resistance against combined TLR agonism and PD-1 blockade
Nishinakamura, H., Shinya, S., Irie, T., Sakihama, S., Naito, T., Watanabe, K., Sugiyama, D., Tamiya, M., Yoshida, T., Hase, T., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adk3160 · Cited by 16
Metastasis-promoting functions of myeloid cells
Kusmartsev, S. A. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10278-y · Cited by 19
Classic versus innovative strategies for immuno-therapy in pancreatic cancer
Formelli, M. G., Palloni, A., Tavolari, S., Deiana, C., Andrini, E., Marco, M. D., Campana, D., Lamberti, G., & Brandi, G. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115671 · Cited by 16
Intranasal Delivery of Recombinant S100A8 Protein Delays Lung Cancer Growth by Remodeling the Lung Immune Microenvironment
Wong, S. W., McCarroll, J. A., Hsu, K., Geczy, C. L., & Tedla, N. T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.826391 · Cited by 15
Co-dependencies in the tumor immune microenvironment
Chen, P., & Dey, P. (2022) · Oncogene · doi:10.1038/s41388-022-02406-7 · Cited by 15
“In Kras-mutated CRC [27], or p53-mutated rhabdomyosarcoma [110] mouse models, the anti-PD-1 therapy resistance is overcome by blocking MDSC infiltration via enforcing IRF2 expression or inhibition of CXCR2.”
Background
Sarcoma Immunotherapy: Confronting Present Hurdles and Unveiling Upcoming Opportunities
Jeong, S., Afroz, S., Kang, D., Noh, J., Suh, J., Kim, J. H., You, H. J., Kang, H. G., Kim, Y., & Kim, J. (2023) · Molecules and Cells · doi:10.14348/molcells.2023.0079 · Cited by 16
“Highfill et al. (2014) showed that G-MDSCs could suppress T cells in rhabdomyosarcoma.”
Targeted immunotherapy and nanomedicine for rhabdomyosarcoma: The way of the future
Morel, V. J., Rössler, J. K., & Bernasconi, M. (2024) · Medicinal Research Reviews · doi:10.1002/med.22059 · Cited by 18
“102 Of note, in this model anti ‐ PD1 therapy prevented tumor growth if initiated early after tumor inoculation, whereas it had only limited benefit when administered later.”
Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1
Fan, J., Shen, X., Wang, Y., Zhou, H., Liu, G., Li, Y., & Xu, Z. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110621 · Cited by 15
Methylcholanthrene-Induced Sarcomas Develop Independently from NOX2-Derived ROS
Ligtenberg, M. A., Çınar, Ö., Holmdahl, R., Mougiakakos, D., & Kiessling, R. W. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129786 · Cited by 15
“In agreement with this and our results here (Fig 2), sarcomas have been shown to induce increases in circulating MDSC as shown in both humans and mice [24,35,36].”
Result
Regulatory T cells crosstalk with tumor cells and endothelium through lymphotoxin signaling
Piao, W., Wu, L., Xiong, Y., Zapas, G., Paluskievicz, C., Oakes, R. S., Pettit, S. M., Sleeth, M. L., Hippen, K. L., Schmitz, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54874-y · Cited by 14
“In addition to their chemotactic properties, CXCL1 is implicated in tumor growth, angiogenesis, and tumorigenesis 51 . ciLT also enhanced effector T cells and reduced MDSCs in TME, which may contribute to ef ﬁ cient tumor regression at the early stage.”
Influential
Myeloid cells meet CD8+ T cell exhaustion in cancer: What, why and how
Zhai, Y., Liang, X., & Deng, M. (2024) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2024.06.04 · Cited by 14
Targeting myeloid cells in pancreatic ductal adenocarcinoma: from primary tumors to liver metastasis
Gong, R., Chen, Y., Chang, D. K.-F., Zhang, H., Liu, Z., & Yu, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1555036 · Cited by 14
Self-citation
Improvement of the Anticancer Efficacy of PD‐1/PD‐L1 Blockade: Advances in Molecular Mechanisms and Therapeutic Strategies
Gao, P., Li, X., Duan, Z., Wang, Y., Li, Y., Wang, J., Luo, K., & Chen, J. (2025) · MedComm · doi:10.1002/mco2.70274 · Cited by 16
B7-H3 in the tumor microenvironment: Implications for CAR T cell therapy in pediatric solid tumors
Jansen, L., Wienke, J., Molkenbur, R., Rössig, C., & Meissner, R. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10294-y · Cited by 15
“MDSCs were found to be enriched also in pediatric solid cancers, along with both correlative and functional evidence in murine models of a key role in local immunosuppression [109–111].”

Authors: Highfill, S. L., Cui, Y., Giles, A. J., Smith, J. P., Zhang, H., Morse, E., Kaplan, R. N., & Mackall, C. L.
Affiliations: National Institutes of Health (US)
Corresponding author: Mackall, Crystal L.
ORCID: Highfill, Steven L.
Cui, Yongzhi
Giles, Amber J.
Zhang, Hua
Kaplan, Rosandra N.
Mackall, Crystal L.
Venue: Science Translational Medicine
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2014-05-21
Volume: 6
Issue: 237
Pages: 237ra67-237ra67
ISSN: 1946-6234 (ISSN-L)
1946-6242
DOI: 10.1126/scitranslmed.3007974
PMC: PMC6980372
OpenAlex: W2171524684
Cited by: 767
References: 50
Citations by year: 2026: 55 · 2025: 62 · 2024: 57 · 2023: 83 · 2022: 73 · 2021: 100 · 2020: 91 · 2019: 60 · 2018: 52 · 2017: 52 · 2016: 38 · 2015: 31 · 2014: 12
FWCI: 20.24
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Science Translational Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health
National Cancer Institute (Z01BC011072, Z01BC010566, Z01SC010289)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
Keywords: CXCR2, myeloid-derived suppressor cells, tumor immune evasion, anti-PD-1 therapy, rhabdomyosarcoma, pediatric sarcoma, interleukin-8, PD-L1, tumor immunosuppression
MeSH terms: Adolescent, Adult, Animals, Antibodies, Monoclonal, Antigens, Ly, Antineoplastic Combined Chemotherapy Protocols, Chemotaxis, Child, Child, Preschool, Female, Humans, Male, Mice, Inbred C57BL, Prognosis, Rhabdomyosarcoma, Time Factors, Neoplastic Stem Cells, Case-Control Studies, Cytokines, Interleukin-8, Mice, Knockout, Tumor Escape, Receptors, Interleukin-8B, CD11b Antigen, Cell Line, Tumor, Tumor Burden, Mice, Chemokine CXCL1, Young Adult, Tumor Microenvironment, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks